Pioneering Medical Innovations
Company Also Expands Sales Team to Include Five Leaders with Extensive Neurovascular Experience CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a company
Significant milestone in company’s mission to advance stroke care CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a company singularly dedicated to answering
Company Founded with Mission to Give Stroke Patients the Best Chance for Optimal Recovery CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a
Acquisition expands portfolio of men’s health in-office procedures with adjunctive therapy for prostate cancer patients Sep 6, 2018 MARLBOROUGH, Mass., Sept.
Boston Scientific (NYSE:BSX) said today it inked a deal worth up to $300 million to acquire Apama Medical and its radiofrequency balloon catheter system designed to treat atrial fibrillation.
Boston Scientific (NYSE:BSX) said today it inked a deal worth up to $300 million to acquire Apama Medical and its radiofrequency balloon catheter system designed to treat atrial fibrillation.
June 5, 2017—The FDA has cleared the use of Claret Medical’s Sentinel cerebral protection system in the U.S., making the device the first and only of its kind on the market that reduces the risk of stroke by capturing and removing debris that can break free during transcatheter aortic valve replacement (TAVR) and cause a stroke, the company said.
June 5, 2017—The First and Only Embolic Protection Device Shown to Reduce TAVR Procedural Strokes by 63 Percent
Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency BEDFORD, Mass.–(BUSINESS WIRE)–Augmenix, Inc.,
February 27, 2017—Claret Medical Inc. announced that in an open public hearing of the US Food and Drug Administration’s Circulatory System Devices Panel held on February 23, virtually all panel members recommended the de novo application of the company’s Sentinel cerebral protection system (CPS) be granted, which would enable commercialization of the device in the United States. A formal vote was not taken, as the Sentinel CPS is a medium-risk accessory device reviewed as a de novo application, advised the company.